NCT07654517
Pirfenidone for Idiopathic Subglottic Stenosis: A Pilot Trial of Tolerability and Feasibility
At risk: Primary completion moved at least 1 year 3 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 1, 2027 to Mar 31, 2029 Show 11 more changesShow less
- Primary endpoint(s) modified
- Start date: Dec 1, 2026 to Apr 1, 2027
- Eligibility criteria expanded, about 17 words
- Enrollment increased: 40 → 44 participants
- Study completion pushed from Dec 1, 2029 to Mar 31, 2030
- Interventions modified
- Study sites: 1 to 2
- Secondary endpoints: 4 to 7
- Study description expanded, about 387 words
- Publications: 11 to 21
- Study title shortened, about 3 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants in this arm will receive oral pirfenidone in addition to standardized intralesional steroid injections for idiopathic subglottic stenosis. Pirfenidone will be titrated from 801 mg/day in Week 1 to 1,602 mg/day in Week 2, then to a maintenance dose of 2,403 mg/day (801 mg three times daily) from Week 3 through Week 52, as tolerated. Study drug will be taken with food to reduce gastrointestinal side effects. All participants will continue to receive protocolized intralesional steroid injections as part of their usual airway management. Participants will be followed during treatment and for an additional post-treatment follow-up period to assess safety, tolerability, and preliminary efficacy.
Participants in this arm will receive an oral placebo in addition to standardized intralesional steroid injections for idiopathic subglottic stenosis. Placebo will be identical to pirfenidone in appearance, packaging and dosing schedule, including titration over the first 2 weeks and maintenance dosing three times daily with food through Week 52. All participants will continue to receive protocolized intralesional steroid injections as part of their usual airway management. Participants will be followed during treatment and for an additional post-treatment follow-up period to assess safety, tolerability, and to compare outcomes with the pirfenidone arm.
Drugs: Pirfenidone, Placebo
Sites
2 sites in 1 country